



Nicholas J. Izzo, Ph.D.

Principal Scientist and Director of Screening
Cognition Therapeutics, Inc.

Nicholas Izzo, Ph.D. is a research biologist with expertise in cell-based assay development and drug discovery. He joined Cognition Therapeutics, Inc. in 2009, where he now leads the company's efforts to develop small molecule drug candidates for the treatment of mild-to-moderate Alzheimer's and other neurodegenerative disorders.

Together with Dr. Susan Catalano and colleagues, Dr. Izzo authored the two seminal papers elucidating the role of the sigma-2/PGRMC1 receptor complex in A β 42 oligomer binding and synaptotoxicity, and the identification of small molecule antagonists to this receptor complex that displace A β 42 oligomers, improving cognitive deficits.

Dr. Izzo is a member of the Society for Neuroscience. He earned a B.S. in chemistry from Georgetown University and a Ph.D. in pharmacology from the University of Virginia. He conducted post-doctoral training at Brigham and Women's Hospital and Harvard Medical School.